Cita APA (7a ed.)

Gendelman, H. E., Zhang, Y., Santamaria, P., Olson, K. E., Schutt, C. R., Bhatti, D., . . . Mosley, R. L. (2017). Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial. Nature Portfolio.

Cita Chicago Style (17a ed.)

Gendelman, Howard E., et al. Evaluation of the Safety and Immunomodulatory Effects of Sargramostim in a Randomized, Double-blind Phase 1 Clinical Parkinson’s Disease Trial. Nature Portfolio, 2017.

Cita MLA (8a ed.)

Gendelman, Howard E., et al. Evaluation of the Safety and Immunomodulatory Effects of Sargramostim in a Randomized, Double-blind Phase 1 Clinical Parkinson’s Disease Trial. Nature Portfolio, 2017.